|
This is an index of reports of adverse events (side effects, adverse reactions, etc.) related to Valcyte (Valganciclovir). Click on the relevant link below to view a selection of reports according to the event's seriousness level and/or the nature of the side effect / adverse reaction. Or scroll down to view all available reports.
Our database includes reports from Jan 2007 to Dec 2007. The information is not vetted and should not be cosidered as verified clinical evidence.
All cases (23)
Cases resulting in a serious event (22)
Cases resulting in death (2)
Cases resulting in life threatening events (2)
Cases resulting in hospitalization (11)
Cases resulting in other serious reactions (13)
Adverse event in 50 year old female receiving Valcyte (Valganciclovir)
Reported by a health professional (non-physician/pharmacist) from United States on 2007-10-15
Patient: 50 year old female
Adverse reactions / side effects: Mania, Drug Interaction, Cognitive Disorder
Suspect drug(s):
Lunesta
Dosage: 6 mg;oral
Administration route: Oral
Paxil
Dosage: qd;oral
Administration route: Oral
Valcyte
Dosage: oral
Administration route: Oral
Other drugs received by patient: Xanax
Adverse event in 62 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Switzerland on 2007-07-31
Patient: 62 year old male
Adverse reactions / side effects: Photosensitivity Reaction, Rash Erythematous, Dermatitis Exfoliative
Adverse event resulted in: hospitalization
Suspect drug(s):
Valcyte
Dosage: long term use.
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
End date: 2007-06-12
Stocrin
Dosage: long term use.
Administration route: Oral
Indication: HIV Infection
Start date: 2006-01-01
End date: 2007-06-25
Pantoprazole Sodium
Dosage: long term use.
Administration route: Oral
End date: 2007-06-25
Lamivudine
Dosage: long term use.
Administration route: Oral
Indication: HIV Infection
End date: 2007-06-25
Viread
Dosage: long term use.
Administration route: Oral
Indication: HIV Infection
End date: 2007-06-25
Keppra
Dosage: long term use. indication reported as epilepsy unspecified.
Administration route: Oral
End date: 2007-06-25
Pradif
Dosage: long term use. indication reported as disorder of prostate, unspecified.
Administration route: Oral
Indication: Prostatic Disorder
End date: 2007-06-25
Duragesic-100
Dosage: long term use. form reported as medicated dressings, transdermal patches. drug reported as durogesi+
Indication: Pain
End date: 2007-06-25
Adverse event in 62 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Switzerland on 2007-07-30
Patient: 62 year old male
Adverse reactions / side effects: Drug Eruption, Photosensitivity Reaction, Incorrect Drug Administration Duration, Rash Erythematous, Dermatitis Exfoliative
Adverse event resulted in: hospitalization
Suspect drug(s):
Duragesic-100
Indication: Pain
Stocrin
Administration route: Oral
Indication: HIV Infection
Pantoprazole Sodium
Administration route: Oral
Indication: Gastritis
Lamivudine
Administration route: Oral
Indication: HIV Infection
Viread
Administration route: Oral
Indication: HIV Infection
Keppra
Administration route: Oral
Indication: Epilepsy
Pradif
Administration route: Oral
Indication: Prostatic Disorder
Valcyte
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Adverse event in 62 year old male receiving Valcyte (Valganciclovir)
Reported by a consumer/non-health professional from Switzerland on 2007-07-25
Patient: 62 year old male
Adverse reactions / side effects: Photosensitivity Reaction, Exfoliative Rash, Rash Erythematous, Dermatitis Exfoliative, Erythema, Toxic Skin Eruption
Adverse event resulted in: hospitalization
Suspect drug(s):
Lamivudine
Dosage: 300mg per day
Administration route: Oral
Indication: HIV Infection
End date: 2007-06-01
Stocrin
Dosage: 600mg per day
Administration route: Oral
Indication: HIV Infection
Start date: 2006-01-01
End date: 2007-06-01
Pantoprazole Sodium
Dosage: 40mg per day
Administration route: Oral
Indication: Gastritis
End date: 2007-06-01
Viread
Dosage: 245mg per day
Administration route: Oral
Indication: HIV Infection
End date: 2007-06-01
Keppra
Dosage: 500mg twice per day
Administration route: Oral
Indication: Epilepsy
End date: 2007-06-01
Pradif
Dosage: 400mg per day
Administration route: Oral
Indication: Prostatic Disorder
End date: 2007-06-01
Durogesic TTS
Dosage: 2.5mg two times per week
Indication: Pain
End date: 2007-06-01
Valcyte
Administration route: Oral
End date: 2007-06-12
Adverse event in 62 year old male receiving Valcyte (Valganciclovir)
Reported by a physician on 2007-07-24
Patient: 62 year old male
Adverse reactions / side effects: Photosensitivity Reaction, Rash Erythematous, Dermatitis Exfoliative
Adverse event resulted in: hospitalization
Suspect drug(s):
Pradif
Administration route: Oral
Indication: Prostatic Disorder
End date: 2007-06-01
Stocrin
Administration route: Oral
Indication: HIV Infection
Start date: 2006-01-01
End date: 2007-06-01
Pantoprazole Sodium
Administration route: Oral
Indication: Gastritis
End date: 2007-06-01
Lamivudine
Administration route: Oral
Indication: HIV Infection
End date: 2007-06-01
Viread
Administration route: Oral
Indication: HIV Infection
End date: 2007-06-01
Keppra
Administration route: Oral
Indication: Epilepsy
End date: 2007-06-01
Duragesic-25
Indication: Pain
End date: 2007-06-01
Valcyte
Administration route: Oral
End date: 2007-06-12
Adverse event in female receiving Valcyte (Valganciclovir)
Reported by a physician from United States on 2007-07-10
Patient: female
Adverse reactions / side effects: Anaemia, Liver Transplant Rejection, Neutropenia, Vaginal Haemorrhage
Adverse event resulted in: hospitalization
Suspect drug(s):
Sirolimus
Administration route: Oral
Indication: Prophylaxis Against Transplant Rejection
Start date: 2007-05-07
End date: 2007-05-15
Sirolimus
Administration route: Oral
Start date: 2007-05-16
End date: 2007-05-22
Sirolimus
Administration route: Oral
Start date: 2007-05-23
End date: 2007-06-05
Sirolimus
Dosage: unknown
Administration route: Oral
Start date: 2007-06-08
Valcyte
Start date: 2007-05-07
End date: 2007-06-05
Mycophenolate Mofetil
Administration route: Oral
Indication: Prophylaxis Against Transplant Rejection
Start date: 2007-05-07
End date: 2007-06-01
Mycophenolate Mofetil
Administration route: Oral
Start date: 2007-06-02
Other drugs received by patient: Omeprazole; Aspirin; Tylenol; Septra; Prednisone
Adverse event in 37 year old male receiving Valcyte (Valganciclovir)
Reported by a consumer/non-health professional from Germany on 2007-07-09
Patient: 37 year old male
Adverse reactions / side effects: Aspermia
Suspect drug(s):
Cellcept
Valcyte
Dosage: therapy completed in october/ november 2006.
End date: 2006-11-01
Rapamune
Indication: Immunosuppression
Decortin
Indication: Immunosuppression
Other drugs received by patient: Antibiotic NOS
Adverse event in 67 year old female receiving Valcyte (Valganciclovir)
Reported by a consumer/non-health professional from United States on 2007-07-06
Patient: 67 year old female
Adverse reactions / side effects: Vomiting, Dehydration
Adverse event resulted in: hospitalization
Suspect drug(s):
Valcyte (Valganciclovir)
Adverse event in female receiving Valcyte (Valganciclovir)
Reported by a physician from United States on 2007-06-29
Patient: female
Adverse reactions / side effects: Anaemia, Liver Transplant Rejection, Neutropenia, Vaginal Haemorrhage
Adverse event resulted in: hospitalization
Suspect drug(s):
Sirolimus
Administration route: Oral
Indication: Prophylaxis Against Transplant Rejection
Start date: 2007-05-07
End date: 2007-05-15
Sirolimus
Administration route: Oral
Start date: 2007-05-16
End date: 2007-05-22
Sirolimus
Administration route: Oral
Start date: 2007-05-23
End date: 2007-06-05
Sirolimus
Dosage: unknown
Administration route: Oral
Start date: 2007-06-08
Valcyte
Start date: 2007-05-07
End date: 2007-06-05
Mycophenolate Mofetil
Administration route: Oral
Indication: Prophylaxis Against Transplant Rejection
Start date: 2007-05-07
End date: 2007-06-01
Mycophenolate Mofetil
Administration route: Oral
Start date: 2007-06-02
Other drugs received by patient: Omeprazole; Acetylsalicylic Acid SRT; Tylenol; Septra; Prednisone TAB
Adverse event in female receiving Valcyte (Valganciclovir)
Reported by a physician from United States on 2007-06-28
Patient: female
Adverse reactions / side effects: Liver Function Test Abnormal, Anaemia, Neutropenia, Vaginal Haemorrhage
Adverse event resulted in: hospitalization
Suspect drug(s):
Sirolimus
Administration route: Oral
Indication: Prophylaxis Against Transplant Rejection
Start date: 2007-05-07
End date: 2007-05-15
Sirolimus
Administration route: Oral
Start date: 2007-05-16
End date: 2007-05-22
Sirolimus
Administration route: Oral
Start date: 2007-05-23
End date: 2007-06-05
Valcyte
Start date: 2007-05-07
End date: 2007-06-05
Mycophenolate Mofetil
Administration route: Oral
Indication: Prophylaxis Against Transplant Rejection
Start date: 2007-05-07
End date: 2007-06-01
Mycophenolate Mofetil
Administration route: Oral
Start date: 2007-06-02
Prednisone TAB
Administration route: Oral
Indication: Prophylaxis Against Transplant Rejection
Start date: 2007-05-07
Other drugs received by patient: Omeprazole; Acetylsalicylic Acid SRT; Tylenol; Septra
Adverse event in 65 year old male receiving Valcyte (Valganciclovir)
Reported by a individual with unspecified qualification from United States on 2007-05-24
Patient: 65 year old male
Adverse reactions / side effects: Cytomegalovirus Infection
Adverse event resulted in: hospitalization
Suspect drug(s):
Valcyte (Valganciclovir)
Adverse event in 5 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-05-16
Patient: 5 year old male, weighing 17.2 kg (37.8 pounds)
Adverse reactions / side effects: Metabolic Acidosis, General Physical Health Deterioration, Hyponatraemia, Erythema, Convulsion, Hypokalaemia, Grand MAL Convulsion, Hypertrichosis, Agranulocytosis, Heart Rate Increased, Electrolyte Imbalance, Leukopenia
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Valcyte
Administration route: Oral
Start date: 2006-09-01
End date: 2006-10-09
Valcyte
Dosage: dosage was decreased.
Administration route: Oral
Start date: 2006-10-10
Other drugs received by patient: Ganciclovir; Rapamune; Decortin; Trileptal; Magnesium Verla Dragees; Enalapril; Lorzaar; Resonium; Sodium Chloride; Unspecified Drug; Aranesp
Adverse event in 48 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-05-11
Patient: 48 year old male
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Neutropenia
Suspect drug(s):
Valcyte
Dosage: indication reported as kidney transplantation (ntx), cmv reactivation.
Administration route: Oral
Start date: 2006-12-14
End date: 2007-02-09
Cellcept
Dosage: dosing frequency: 2x. indication reported as ntx, cmv immunosuppression.
Administration route: Oral
Start date: 2007-01-31
End date: 2007-03-05
Prograf
Dosage: frequency: 2x. indication reported as ntx, cmv immunosuppression.
Administration route: Oral
Indication: Immunosuppression
Start date: 2007-01-31
End date: 2007-03-05
Decortin H
Dosage: frequency: 1x. indication reported as ntx, cmv immunosuppression.
Administration route: Oral
Indication: Immunosuppression
Start date: 2007-01-31
End date: 2007-03-05
Adverse event in 5 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-04-13
Patient: 5 year old male, weighing 17.2 kg (37.8 pounds)
Adverse reactions / side effects: Agranulocytosis, Metabolic Acidosis, Electrolyte Imbalance, Convulsion
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Valcyte
Administration route: Oral
Start date: 2006-09-01
End date: 2006-09-27
Valcyte
Dosage: dosage was decreased.
Administration route: Oral
Start date: 2006-09-28
Other drugs received by patient: Ganciclovir; Rapamune; Decortin; Trileptal; Magnesium Verla Dragees; Enalapril Maleate; Lorzaar; Resonium; Sodium Chloride; Unspecified Drug; Aranesp
Adverse event in 48 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-04-05
Patient: 48 year old male
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Neutropenia
Suspect drug(s):
Valcyte
Dosage: indication reported as kidney transplantation (ntx), cmv reactivation.
Administration route: Oral
Start date: 2006-12-14
End date: 2007-02-09
Cellcept
Dosage: dosing frequency: 2x. indication reported as ntx, cmv immunosuppression.
Administration route: Oral
Start date: 2007-01-31
End date: 2007-03-05
Prograf
Dosage: frequency: 2x. indication reported as ntx, cmv immunosuppression.
Administration route: Oral
Indication: Immunosuppression
Start date: 2007-01-31
End date: 2007-03-05
Decortin H
Dosage: frequency: 1x. indication reported as ntx, cmv immunosuppression.
Administration route: Oral
Indication: Immunosuppression
Start date: 2007-01-31
End date: 2007-03-05
Adverse event in male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-03-22
Patient: male
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Neutropenia
Suspect drug(s):
Valcyte (Valganciclovir)
Adverse event in male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-03-16
Patient: male
Adverse reactions / side effects: Pneumocystis Jiroveci Pneumonia, Leukopenia
Suspect drug(s):
Valcyte (Valganciclovir)
Adverse event in 53 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-01-26
Patient: 53 year old male, weighing 62.0 kg (136.4 pounds)
Adverse reactions / side effects: Multi-Organ Failure, C-Reactive Protein Increased, General Physical Health Deterioration
Adverse event resulted in: death
Suspect drug(s):
Valcyte (Valganciclovir)
Other drugs received by patient: Cellcept
Adverse event in 53 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-01-26
Patient: 53 year old male, weighing 62.0 kg (136.4 pounds)
Adverse reactions / side effects: Multi-Organ Failure, C-Reactive Protein Increased, General Physical Health Deterioration
Adverse event resulted in: death
Suspect drug(s):
Valcyte (Valganciclovir)
Other drugs received by patient: Cellcept
Adverse event in 56 year old female receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-01-25
Patient: 56 year old female, weighing 49.5 kg (108.9 pounds)
Adverse reactions / side effects: Agranulocytosis
Suspect drug(s):
Cellcept
Start date: 2005-04-15
End date: 2005-05-15
Cellcept
Start date: 2005-05-15
End date: 2005-07-27
Valcyte
Start date: 2005-04-15
End date: 2005-07-17
Valcyte
Start date: 2005-08-19
End date: 2005-09-15
Valcyte
Start date: 2005-10-15
Valcyte
Dosage: long term treatment for the indication of ebv infection.
Start date: 2006-02-28
Other drugs received by patient: Sandimmune; Cyclosporine; Prednisone; Epivir; Pantoprazol; Ursodiol; ACC Long; Magnesium Verla; Multivitamin NOS; Tavor; Venlafaxine HCL; Saroten; Saroten
Adverse event in 52 year old female receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-01-17
Patient: 52 year old female, weighing 64.0 kg (140.8 pounds)
Adverse reactions / side effects: Creatinine Renal Clearance Decreased, C-Reactive Protein Increased, Platelet Count Decreased, Blood Creatinine Increased, Leukopenia
Suspect drug(s):
Valcyte (Valganciclovir)
Other drugs received by patient: Foscavir
Adverse event in 53 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-01-17
Patient: 53 year old male, weighing 62.0 kg (136.4 pounds)
Adverse reactions / side effects: C-Reactive Protein Increased, General Physical Health Deterioration
Suspect drug(s):
Valcyte (Valganciclovir)
Other drugs received by patient: Cellcept
Adverse event in 64 year old male receiving Valcyte (Valganciclovir)
Reported by a physician from Germany on 2007-01-16
Patient: 64 year old male, weighing 80.0 kg (176.0 pounds)
Adverse reactions / side effects: C-Reactive Protein Increased, Leukopenia
Suspect drug(s):
Valcyte
Administration route: Oral
Start date: 2005-08-30
End date: 2005-10-18
Valcyte
Administration route: Oral
Start date: 2005-10-19
End date: 2005-11-15
|
